67389-47-3

Upstream product

• 47173-80-8 N-Boc-D-serine(Bzl)-OH 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 74-88-4 methyl iodide 
• 80-11-5 N-methyl-N-nitrosotoluene-p-sulfonamide 

Downstream Products

• 350685-50-6 tert-butyl (R)-(1-(benzyloxy)-3-oxopropan-2-yl)carbamate 
• 752251-06-2 (S)-3-amino-6,7-bis(OBn)-1,1-dimethyl-1,2,3,4-tetrahydroquinolin-1-ium L-ser(OBn)-D-ser (OBn)-BocL-thr(OBn) 
• 752251-07-3 H-L-Thr(OBn)-D-Ser(OBn)-LSer(OBn)-(3S)-THQ(OBn) 
• 752251-20-0 (2R)-3-benzyloxy-2-((2S)-3-benzyloxy-2-tert-butoxycarbonylamino-butyrylamino)propionic acid 
• 752251-21-1 (2R)-3-benzyloxy-2-((2S)-3-benzyloxy-2-tert-butoxycarbonylamino-butyrylamino)propionic acid methyl ester 
• 84907-81-3 (2R)-3-benzyloxy-2-aminopropanoic acid methyl ester 
• 79069-15-1 tert-butyl N-[(1S)-1-(benzyloxymethyl)-2-hydroxy-ethyl]carbamate 

Relevant academic research and scientific papers

Total synthesis of (-)-aplaminal

(Chemical Equation Presented) The total synthesis and assignment of absolute configuration of (-)-aplaminal (1), a cytotoxic metabolite from a sea hare possessing a triazobicyclo[3.2.1]octane skeleton, has been achieved. The synthesis entailed condensatio

Growth hormone secretagogues

What is disclosed are growth hormone secretagogues, and their uses, of the formula wherein R1 is C6H5CH2OCH2—, C6H5(CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1to C6alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.

Combinations of β3 agonists and growth hormone secretagogues

This invention is directed to pharmaceutical compositions comprising β3adrenergic agonists including (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl)acetic acid and growth hormone or growth hormone secretagogues, prodrugs thereof or pharmaceutically acceptable salts of said compounds or said prodrugs. The invention is also directed to methods of using those compositions in the treatment of obesity, diabetes, hypertension and frailty in animals and particularly in humans.

Treatment of congestive heart failure with growth hormone secretagogues

The present invention is directed to methods for the modulation of cardiac function which comprise the administration of certain compounds, as defined herein, having growth hormone secretagogue activity.

Synthesis of an enantiomerically pure serine-derived thiazole

Previously reported methods for preparing enantiomerically pure thiazoles are inadequate for the synthesis of inherently labile O-alkyl serine-derived thiazoles. The intermediate N-Boc-(O-methylseryl) thiazolines are very susceptible to tautomerization, e